Figure 5.

Low tumor NAT1 expression is associated with low survival in patients with breast cancer treated with TAM. Kaplan-Meier survival curve analysis was performed using tumor NAT1 expression levels (low or high) in two publicly available data sets for patients with estrogen receptor-positive breast cancer who received adjuvant TAM treatment. Survival curves based on mRNA expression data from (A) 89 patients and (B) 261 patients receiving TAM treatment. The red lines and numbers indicate high tumor NAT1 expression and the black lines and numbers indicate low tumor NAT1 expression. HR and log rank P-values were calculated based on data from the NCBI GEO database (accession numbers GSE2990 and GSE20685, respectively). HR, hazard ratio; NAT1, N-acetyltransferase 1; TAM, tamoxifen.